83 related articles for article (PubMed ID: 11103436)
1. Fas-mediated cell death in toxic epidermal necrolysis and graft-versus-host disease: potential for therapeutic inhibition.
French LE; Tschopp J
Schweiz Med Wochenschr; 2000 Nov; 130(44):1656-61. PubMed ID: 11103436
[TBL] [Abstract][Full Text] [Related]
2. Protein-based therapeutic approaches targeting death receptors.
French LE; Tschopp J
Cell Death Differ; 2003 Jan; 10(1):117-23. PubMed ID: 12655300
[TBL] [Abstract][Full Text] [Related]
3. Death receptors in cutaneous biology and disease.
Wehrli P; Viard I; Bullani R; Tschopp J; French LE
J Invest Dermatol; 2000 Aug; 115(2):141-8. PubMed ID: 10951228
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic effect of novel anti-human Fas antibody HFE7a on graft-versus-host disease model.
Kuwahara H; Tani Y; Ogawa Y; Takaichi Y; Shiraishi A; Ohtsuki M
Clin Immunol; 2001 Jun; 99(3):340-6. PubMed ID: 11358429
[TBL] [Abstract][Full Text] [Related]
5. Fas/CD95 death receptor and lipid rafts: new targets for apoptosis-directed cancer therapy.
Mollinedo F; Gajate C
Drug Resist Updat; 2006; 9(1-2):51-73. PubMed ID: 16687251
[TBL] [Abstract][Full Text] [Related]
6. Toxic epidermal necrolysis: current evidence, practical management and future directions.
Chave TA; Mortimer NJ; Sladden MJ; Hall AP; Hutchinson PE
Br J Dermatol; 2005 Aug; 153(2):241-53. PubMed ID: 16086734
[TBL] [Abstract][Full Text] [Related]
7. Use of intravenous immunoglobulin in toxic epidermal necrolysis and Stevens-Johnson syndrome: our current understanding.
French LE; Trent JT; Kerdel FA
Int Immunopharmacol; 2006 Apr; 6(4):543-9. PubMed ID: 16504917
[TBL] [Abstract][Full Text] [Related]
8. [Epidermic necrolysis: advances in pathogenesis].
Roujeau JC
Ann Dermatol Venereol; 2000 May; 127(5):546-7. PubMed ID: 10863193
[No Abstract] [Full Text] [Related]
9. Potentiation of Fas-mediated apoptosis by an engineered glycosylphosphatidylinositol-linked Fas.
Legembre P; Moreau P; Daburon S; Moreau JF; Taupin JL
Cell Death Differ; 2002 Mar; 9(3):329-39. PubMed ID: 11859415
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical evaluation of toxic epidermal necrolysis treated with human intravenous immunoglobulin.
Romanelli P; Schlam E; Green JB; Trent JT; Ricotti C; Elgart GW; Kirsner RS; Kerdel FA
G Ital Dermatol Venereol; 2008 Aug; 143(4):229-33. PubMed ID: 18833079
[TBL] [Abstract][Full Text] [Related]
11. Fas/FasL interaction: a novel immune therapy approach with immobilized biologicals.
Scholz M; Cinatl J
Med Res Rev; 2005 May; 25(3):331-42. PubMed ID: 15599929
[TBL] [Abstract][Full Text] [Related]
12. Severe cutaneous adverse reactions to drugs.
Chia FL; Leong KP
Curr Opin Allergy Clin Immunol; 2007 Aug; 7(4):304-9. PubMed ID: 17620821
[TBL] [Abstract][Full Text] [Related]
13. Frequent loss of Fas expression and function in human lung tumours with overexpression of FasL in small cell lung carcinoma.
Viard-Leveugle I; Veyrenc S; French LE; Brambilla C; Brambilla E
J Pathol; 2003 Oct; 201(2):268-77. PubMed ID: 14517844
[TBL] [Abstract][Full Text] [Related]
14. Abnormal Fas/FasL and caspase-3-mediated apoptotic signaling pathways of T lymphocyte subset in patients with systemic lupus erythematosus.
Xue C; Lan-Lan W; Bei C; Jie C; Wei-Hua F
Cell Immunol; 2006 Feb; 239(2):121-8. PubMed ID: 16808908
[TBL] [Abstract][Full Text] [Related]
15. ECP-treated lymphocytes of chronic graft-versus-host disease patients undergo apoptosis which involves both the Fas/FasL system and the Bcl-2 protein family.
Di Renzo M; Rubegni P; Sbano P; Cuccia A; Castagnini C; Pompella G; Pasqui AL; Capecchi PL; Auteri A; Laghi Pasini F; Fimiani M
Arch Dermatol Res; 2003 Sep; 295(5):175-82. PubMed ID: 12883827
[TBL] [Abstract][Full Text] [Related]
16. Induction of Fas expression and augmentation of Fas/Fas ligand-mediated apoptosis by the synthetic retinoid CD437 in human lung cancer cells.
Sun SY; Yue P; Hong WK; Lotan R
Cancer Res; 2000 Nov; 60(22):6537-43. PubMed ID: 11103825
[TBL] [Abstract][Full Text] [Related]
17. Expression of Fas and Fas-ligand in donor hematopoietic stem and progenitor cells is dissociated from the sensitivity to apoptosis.
Pearl-Yafe M; Yolcu ES; Stein J; Kaplan O; Shirwan H; Yaniv I; Askenasy N
Exp Hematol; 2007 Oct; 35(10):1601-12. PubMed ID: 17889725
[TBL] [Abstract][Full Text] [Related]
18. Toxic epidermal necrolysis treated with low-dose intravenous immunoglobulin: immunohistochemical study of Fas and Fas-ligand expression.
Ito K; Hara H; Okada T; Shimojima H; Suzuki H
Clin Exp Dermatol; 2004 Nov; 29(6):679-80. PubMed ID: 15550154
[No Abstract] [Full Text] [Related]
19. Toxic epidermal necrolysis and intravenous immunoglobulin: a review.
Trent J; Halem M; French LE; Kerdel F
Semin Cutan Med Surg; 2006 Jun; 25(2):91-3. PubMed ID: 16908399
[TBL] [Abstract][Full Text] [Related]
20. Stevens-Johnson syndrome and toxic epidermal necrolysis.
Borchers AT; Lee JL; Naguwa SM; Cheema GS; Gershwin ME
Autoimmun Rev; 2008 Sep; 7(8):598-605. PubMed ID: 18603022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
